News Express

Science News: Serial Nerve Conduction Studies in Guillain-Barré Syndrome: Its Usefulness and Precise Timing

March 11, 2025

This multicenter retrospective study aimed to assess the usefulness of serial nerve conduction studies in patients with Guillain-Barré syndrome who undergo nerve conduction studies at an early stage.

2025 Medicare Physician Fee Schedule and Advocacy Opportunity

March 10, 2025

2025 AANEM & Wake Forest Francis O. Walker Neuromuscular Ultrasound Course

March 03, 2025

Plan to attend the Francis O. Walker Neuromuscular Ultrasound Workshop presented by Wake Forest University School of Medicine and AANEM.

2025 Medicare Physician Fee Schedule – Updates You Should Know About

February 27, 2025

On Nov. 2, 2024, the Centers for Medicare & Medicaid Services (CMS) issued the Final Rule of the 2025 Physician Fee Schedule (PFS) and Quality Payment Program (QPP) updates. This is a summary of some of the items in the 3000+ page document that may affect you or your practice.

Science News: Optimization of Muscle Selection for Needle Electromyography in Isolated C6 Root Lesion: A Prospective Chart Review Study

February 25, 2025

The aim of the study was to evaluate muscles with more prominent needle electromyographic findings to optimize needle EMG screening of isolated C6 radiculopathy in patients with C6 root lesions.

Science News: Use of Baclofen as a Treatment for Nocturnal Calf Cramps in Individuals With Lumbar Spinal Stenosis: A Prospective Randomized Study

February 17, 2025

A group of 40 adults with spinal stenosis who complained of nocturnal calf cramps (NCCs) more than once a week were enrolled in a study to measure the use of baclofen as a treatment for NCCs.

Inside the Match — An Applicant’s Experience Using the AANEM Fellowship Match Portal

February 12, 2025

Hear from Amber Vocelle, DO, PhD, Member of the AANEM Young Leadership Council, on her experience as an applicant in the AANEM Fellowship Match Portal.

Patient Safety: Toxic Neuropathy Following Treatment With Linezolid

January 31, 2025

Linezolid is an antibiotic used for treatment of drug resistant gram-positive bone and joint infections and multidrug resistant tuberculosis. Prolonged treatment courses longer than 28 days have been associated with peripheral neuropathy and optic neuropathy. The neuropathy may become irreversible with prolonged use. Early recognition of toxic neuropathy and stopping neurotoxic medications increase the chance of symptom improvement.

Trainee Talk: Making the Most of Your Neuromuscular Fellowship

January 30, 2025

Dr. Michael P. Skolka relives his fellowship experience and shares tips and tricks for making the most our of your fellowship term.

Science News: A Study on the Epidemiology of COVID-19 Related Guillain-Barré Syndrome in the United States

January 30, 2025

Several neurological complications have been reported with COVID-19, including Guillain–Barré syndrome (GBS). Researchers looked at incidence, baseline characteristics, and in-hospital outcomes of COVID 19–associated GBS in the United States.

AANEM Publishes New International Consensus Guidance for the Management of Glucocorticoid Related Complications in Neuromuscular Disease

January 28, 2025

After several years of extensive work, AANEM’s Practice Issues Review Panel (PIRP)’s Glucocorticoid Related Complications in NM Diseases task force recently published its international consensus statement in Muscle & Nerve.

AANEM Publishes New Statement on Environmental Awareness in Electrodiagnostic Medicine

January 21, 2025

AANEM’s Professional Practice Committee has published a new position statement on the importance of environmental awareness in NM & EDX medicine called: Environmental Awareness in Electrodiagnostic Medicine.

Science News: Musician’s Dystonia in a Percussionist - Clinical Video Analysis and Botulinum Toxin Intervention: A Case Report

January 17, 2025

This is a case of a 63 year old male percussionist with musician’s focal hand dystonia treated with botulinum toxin.

Patient Safety: Impact of Antibiotics in Patients With Myasthenia Gravis

January 16, 2025

A question from AANEM's Quality and Patient Safety Committee on the impact of antibiotics in patients with MG.

Science News: Rate and Characteristics of Inflammatory Neuropathies Associated With Brentuximab Vedotin Therapy

January 02, 2025

Brentuximab-induced neuropathy (BV-CN) can present as a mild sensory neuropathy or a severe inflammatory form (BV-IN) with significant motor impairment. BV-IN often requires treatment discontinuation and immunotherapy.

Trainee Talk: Resources to Review Before Your Upcoming EMG Rotation as a Medical Student or Resident

December 18, 2024

Dr. Nakul Katyal highlights the AANEM's Training Partnership Program (TPP) as a key resource for preparing for an EMG rotation. TPP offers lectures, videos, and self-study materials to help build a strong foundation in peripheral anatomy, NCS, and EMG.

Science News: Physical Strain of Walking in People With Neuromuscular Diseases Is High and Relates To Step Activity in Daily Life

December 17, 2024

The study examined the physical strain of walking in individuals with neuromuscular disease (NMD) by measuring VO2walk and VO2peak. It also explored the relationship between daily step count, time in moderate-to-vigorous physical activity, and walking strain.

Science News: Living With Dysphagia: A Survey Exploring the Experiences of Adults Living With Neuromuscular Disease and Their Caregivers in the United Kingdom

December 06, 2024

This cross-sectional study used surveys to explore dysphagia experiences in neuromuscular disease.

AANEM Attends AMA House of Delegates Meeting

November 25, 2024

AANEM updates from the AMA’s House of Delegates (HOD) interim meeting in Orlando, Florida in mid-November.

Science News: Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis

November 20, 2024

This phase 1 pilot study showed that phenylbutyric acid (PBA) is safe and well-tolerated in treating inclusion body myositis (IBM). While limited by small sample size, the study found significant biomarker improvement, supporting further research on PBA's therapeutic potential.